{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T10:57:44Z","timestamp":1778497064098,"version":"3.51.4"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2019,4,26]],"date-time":"2019-04-26T00:00:00Z","timestamp":1556236800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000848","name":"University of Edinburgh","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000848","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virchows Arch"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1007\/s00428-019-02571-3","type":"journal-article","created":{"date-parts":[[2019,4,26]],"date-time":"2019-04-26T05:04:21Z","timestamp":1556255061000},"page":"681-689","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["IQN path ASBL report from the first European cfDNA consensus meeting: expert opinion on the minimal requirements for clinical ctDNA testing"],"prefix":"10.1007","volume":"474","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9361-6012","authenticated-orcid":false,"given":"Zandra C.","family":"Deans","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel","family":"Butler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melanie","family":"Cheetham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabeth M. C.","family":"Dequeker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer A.","family":"Fairley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Fenizia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacqueline A.","family":"Hall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cleo","family":"Keppens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola","family":"Normanno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ed","family":"Schuuring","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon J.","family":"Patton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,4,26]]},"reference":[{"key":"2571_CR1","unstructured":"Definition of liquid biopsy - NCI Dictionary of Cancer Terms - National Cancer Institute. \n                    https:\/\/www.cancer.gov\/publications\/dictionaries\/cancer-terms\/def\/liquid-biopsy\n                    \n                  . Accessed 28 Jan 2019"},{"key":"2571_CR2","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1007\/s00428-017-2222-z","volume":"471","author":"ZC Deans","year":"2017","unstructured":"Deans ZC, Williams H, Dequeker EMC et al (2017) Review of the implementation of plasma ctDNA testing on behalf of IQN path ASBL: a perspective from an EQA providers\u2019 survey. Virchows Arch 471:809\u2013813. \n                    https:\/\/doi.org\/10.1007\/s00428-017-2222-z","journal-title":"Virchows Arch"},{"key":"2571_CR3","doi-asserted-by":"publisher","unstructured":"Keppens C, Dequeker EMC, Patton SJ et al (2018) International pilot external quality assessment scheme for analysis and reporting of circulating tumour DNA. BMC Cancer 18. \n                    https:\/\/doi.org\/10.1186\/s12885-018-4694-x","DOI":"10.1186\/s12885-018-4694-x"},{"key":"2571_CR4","doi-asserted-by":"publisher","first-page":"321","DOI":"10.5858\/arpa.2017-0388-CP","volume":"142","author":"NI Lindeman","year":"2018","unstructured":"Lindeman NI, Cagle PT, Aisner DL, Arcila ME, Beasley MB, Bernicker EH, Colasacco C, Dacic S, Hirsch FR, Kerr K, Kwiatkowski DJ, Ladanyi M, Nowak JA, Sholl L, Temple-Smolkin R, Solomon B, Souter LH, Thunnissen E, Tsao MS, Ventura CB, Wynes MW, Yatabe Y (2018) Updated molecular testing guideline for the selection of lung Cancer patients for treatment with targeted tyrosine kinase inhibitors: guideline from the College of American Pathologists, the International Association for the Study of Lung Cancer, and the. Arch Pathol Lab Med 142:321\u2013346. \n                    https:\/\/doi.org\/10.5858\/arpa.2017-0388-CP","journal-title":"Arch Pathol Lab Med"},{"key":"2571_CR5","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1200\/JCO.2012.45.2011","volume":"32","author":"LA Diaz","year":"2014","unstructured":"Diaz LA, Bardelli A (2014) Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol 32:579\u2013586. \n                    https:\/\/doi.org\/10.1200\/JCO.2012.45.2011","journal-title":"J Clin Oncol"},{"key":"2571_CR6","doi-asserted-by":"publisher","first-page":"13870","DOI":"10.18632\/oncotarget.24493","volume":"9","author":"PA Boonstra","year":"2018","unstructured":"Boonstra PA, ter Elst A, Tibbesma M, Bosman LJ, Mathijssen R, Atrafi F, van Coevorden F, Steeghs N, Farag S, Gelderblom H, van der Graaf WTA, Desar IME, Maier J, Overbosch J, Suurmeijer AJH, Gietema J, Schuuring E, Reyners AKL (2018) A single digital droplet PCR assay to detect multiple KIT exon 11 mutations in tumor and plasma from patients with gastrointestinal stromal tumors. Oncotarget 9:13870\u201313883. \n                    https:\/\/doi.org\/10.18632\/oncotarget.24493","journal-title":"Oncotarget"},{"key":"2571_CR7","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1038\/nm.3870","volume":"21","author":"G Siravegna","year":"2015","unstructured":"Siravegna G, Mussolin B, Buscarino M, Corti G, Cassingena A, Crisafulli G, Ponzetti A, Cremolini C, Amatu A, Lauricella C, Lamba S, Hobor S, Avallone A, Valtorta E, Rospo G, Medico E, Motta V, Antoniotti C, Tatangelo F, Bellosillo B, Veronese S, Budillon A, Montagut C, Racca P, Marsoni S, Falcone A, Corcoran RB, di Nicolantonio F, Loupakis F, Siena S, Sartore-Bianchi A, Bardelli A (2015) Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nat Med 21:795\u2013801. \n                    https:\/\/doi.org\/10.1038\/nm.3870","journal-title":"Nat Med"},{"key":"2571_CR8","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1093\/annonc\/mdv176","volume":"26","author":"N Normanno","year":"2015","unstructured":"Normanno N, Rachiglio AM, Lambiase M, Martinelli E, Fenizia F, Esposito C, Roma C, Troiani T, Rizzi D, Tatangelo F, Botti G, Maiello E, Colucci G, Ciardiello F (2015) Heterogeneity of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer and potential effects on therapy in the CAPRI GOIM trial. Ann Oncol 26:1710\u20131714. \n                    https:\/\/doi.org\/10.1093\/annonc\/mdv176","journal-title":"Ann Oncol"},{"key":"2571_CR9","doi-asserted-by":"publisher","first-page":"224ra24","DOI":"10.1126\/scitranslmed.3007094","volume":"6","author":"C Bettegowda","year":"2014","unstructured":"Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, Bartlett BR, Wang H, Luber B, Alani RM, Antonarakis ES, Azad NS, Bardelli A, Brem H, Cameron JL, Lee CC, Fecher LA, Gallia GL, Gibbs P, le D, Giuntoli RL, Goggins M, Hogarty MD, Holdhoff M, Hong SM, Jiao Y, Juhl HH, Kim JJ, Siravegna G, Laheru DA, Lauricella C, Lim M, Lipson EJ, Marie SKN, Netto GJ, Oliner KS, Olivi A, Olsson L, Riggins GJ, Sartore-Bianchi A, Schmidt K, Shih M, Oba-Shinjo SM, Siena S, Theodorescu D, Tie J, Harkins TT, Veronese S, Wang TL, Weingart JD, Wolfgang CL, Wood LD, Xing D, Hruban RH, Wu J, Allen PJ, Schmidt CM, Choti MA, Velculescu VE, Kinzler KW, Vogelstein B, Papadopoulos N, Diaz LA (2014) Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med 6:224ra24\u2013224ra24. \n                    https:\/\/doi.org\/10.1126\/scitranslmed.3007094","journal-title":"Sci Transl Med"},{"key":"2571_CR10","doi-asserted-by":"publisher","first-page":"8839","DOI":"10.1038\/ncomms9839","volume":"6","author":"L Mattos-Arruda De","year":"2015","unstructured":"De Mattos-Arruda L, Mayor R, Ng CKY et al (2015) Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma. Nat Commun 6:8839. \n                    https:\/\/doi.org\/10.1038\/ncomms9839","journal-title":"Nat Commun"},{"key":"2571_CR11","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1093\/annonc\/mdx112","volume":"28","author":"J Grasselli","year":"2017","unstructured":"Grasselli J, Elez E, Carat\u00f9 G, Matito J, Santos C, Macarulla T, Vidal J, Garcia M, Vi\u00e9itez JM, Pa\u00e9z D, Falc\u00f3 E, Lopez Lopez C, Aranda E, Jones F, Sikri V, Nuciforo P, Fasani R, Tabernero J, Montagut C, Azuara D, Dienstmann R, Salazar R, Vivancos A (2017) Concordance of blood- and tumor-based detection of RAS mutations to guide anti-EGFR therapy in metastatic colorectal cancer. Ann Oncol 28:1294\u20131301. \n                    https:\/\/doi.org\/10.1093\/annonc\/mdx112","journal-title":"Ann Oncol"},{"key":"2571_CR12","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1093\/annonc\/mdx125","volume":"28","author":"J Vidal","year":"2017","unstructured":"Vidal J, Muinelo L, Dalmases A, Jones F, Edelstein D, Iglesias M, Orrillo M, Abalo A, Rodr\u00edguez C, Brozos E, Vidal Y, Candamio S, V\u00e1zquez F, Ruiz J, Guix M, Visa L, Sikri V, Albanell J, Bellosillo B, L\u00f3pez R, Montagut C (2017) Plasma ctDNA RAS mutation analysis for the diagnosis and treatment monitoring of metastatic colorectal cancer patients. Ann Oncol 28:1325\u20131332. \n                    https:\/\/doi.org\/10.1093\/annonc\/mdx125","journal-title":"Ann Oncol"},{"key":"2571_CR13","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1093\/annonc\/mdx417","volume":"29","author":"N Normanno","year":"2018","unstructured":"Normanno N, Esposito Abate R, Lambiase M, Forgione L, Cardone C, Iannaccone A, Sacco A, Rachiglio AM, Martinelli E, Rizzi D, Pisconti S, Biglietto M, Bordonaro R, Troiani T, Latiano TP, Giuliani F, Leo S, Rinaldi A, Maiello E, Ciardiello F, CAPRI-GOIM Investigators (2018) RAS testing of liquid biopsy correlates with the outcome of metastatic colorectal cancer patients treated with first-line FOLFIRI plus cetuximab in the CAPRI-GOIM trial. Ann Oncol 29:112\u2013118. \n                    https:\/\/doi.org\/10.1093\/annonc\/mdx417","journal-title":"Ann Oncol"},{"key":"2571_CR14","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1097\/JTO.0000000000000643","volume":"10","author":"A Marchetti","year":"2015","unstructured":"Marchetti A, Palma JF, Felicioni L, de Pas TM, Chiari R, del Grammastro M, Filice G, Ludovini V, Brandes AA, Chella A, Malorgio F, Guglielmi F, de Tursi M, Santoro A, Crin\u00f2 L, Buttitta F (2015) Early prediction of response to tyrosine kinase inhibitors by quantification of EGFR mutations in plasma of NSCLC patients. J Thorac Oncol 10:1437\u20131443. \n                    https:\/\/doi.org\/10.1097\/JTO.0000000000000643","journal-title":"J Thorac Oncol"},{"key":"2571_CR15","doi-asserted-by":"publisher","first-page":"3375","DOI":"10.1200\/JCO.2016.66.7162","volume":"34","author":"GR Oxnard","year":"2016","unstructured":"Oxnard GR, Thress KS, Alden RS, Lawrance R, Paweletz CP, Cantarini M, Yang JCH, Barrett JC, J\u00e4nne PA (2016) Association between plasma genotyping and outcomes of treatment with Osimertinib (AZD9291) in advanced non\u2013small-cell lung Cancer. J Clin Oncol 34:3375\u20133382. \n                    https:\/\/doi.org\/10.1200\/JCO.2016.66.7162","journal-title":"J Clin Oncol"},{"key":"2571_CR16","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.5858\/arpa.2018-0901-SA","volume":"142","author":"JD Merker","year":"2018","unstructured":"Merker JD, Oxnard GR, Compton C, Diehn M, Hurley P, Lazar AJ, Lindeman N, Lockwood CM, Rai AJ, Schilsky RL, Tsimberidou AM, Vasalos P, Billman BL, Oliver TK, Bruinooge SS, Hayes DF, Turner NC (2018) Circulating tumor DNA analysis in patients with cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. Arch Pathol Lab Med 142:1242\u20131253. \n                    https:\/\/doi.org\/10.5858\/arpa.2018-0901-SA","journal-title":"Arch Pathol Lab Med"},{"key":"2571_CR17","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41576-018-0071-5","volume":"20","author":"E Heitzer","year":"2019","unstructured":"Heitzer E, Haque IS, Roberts CES, Speicher MR (2019) Current and future perspectives of liquid biopsies in genomics-driven oncology. Nat Rev Genet 20:71\u201388. \n                    https:\/\/doi.org\/10.1038\/s41576-018-0071-5","journal-title":"Nat Rev Genet"},{"key":"2571_CR18","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1634\/theoncologist.2017-0425","volume":"23","author":"L Odogwu","year":"2018","unstructured":"Odogwu L, Mathieu L, Goldberg KB, Blumenthal GM, Larkins E, Fiero MH, Rodriguez L, Bijwaard K, Lee EY, Philip R, Fan I, Donoghue M, Keegan P, McKee A, Pazdur R (2018) FDA benefit-risk assessment of Osimertinib for the treatment of metastatic non-small cell lung Cancer harboring epidermal growth factor receptor T790M mutation. Oncologist 23:353\u2013359. \n                    https:\/\/doi.org\/10.1634\/theoncologist.2017-0425","journal-title":"Oncologist"},{"key":"2571_CR19","doi-asserted-by":"publisher","unstructured":"Warren JD, Xiong W, Bunker AM, Vaughn CP, Furtado LV, Roberts WL, Fang JC, Samowitz WS, Heichman KA (2011) Septin 9 methylated DNA is a sensitive and specific blood test for colorectal cancer. BMC Med 9(133). \n                    https:\/\/doi.org\/10.1186\/1741-7015-9-133","DOI":"10.1186\/1741-7015-9-133"},{"key":"2571_CR20","unstructured":"ISO 15189:2012 - Medical laboratories -- Requirements for quality and competence. \n                    https:\/\/www.iso.org\/standard\/56115.html\n                    \n                  . Accessed 28 Jan 2019"},{"key":"2571_CR21","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.cell.2015.11.050","volume":"164","author":"MW Snyder","year":"2016","unstructured":"Snyder MW, Kircher M, Hill AJ, Daza RM, Shendure J (2016) Cell-free DNA comprises an in vivo nucleosome footprint that informs its tissues-of-origin. Cell 164:57\u201368. \n                    https:\/\/doi.org\/10.1016\/j.cell.2015.11.050","journal-title":"Cell"},{"key":"2571_CR22","doi-asserted-by":"publisher","first-page":"665","DOI":"10.21037\/tlcr.2016.12.03","volume":"5","author":"C P\u00e9rez-Barrios","year":"2016","unstructured":"P\u00e9rez-Barrios C, Nieto-Alcolado I, Torrente M, Jim\u00e9nez-S\u00e1nchez C, Calvo V, Gutierrez-Sanz L, Palka M, Donoso-Navarro E, Provencio M, Romero A (2016) Comparison of methods for circulating cell-free DNA isolation using blood from cancer patients: impact on biomarker testing. Transl Lung Cancer Res 5:665\u2013672. \n                    https:\/\/doi.org\/10.21037\/tlcr.2016.12.03","journal-title":"Transl Lung Cancer Res"},{"key":"2571_CR23","doi-asserted-by":"publisher","first-page":"6873","DOI":"10.1007\/s00216-015-8846-4","volume":"407","author":"F Mauger","year":"2015","unstructured":"Mauger F, Dulary C, Daviaud C, Deleuze JF, Tost J (2015) Comprehensive evaluation of methods to isolate, quantify, and characterize circulating cell-free DNA from small volumes of plasma. Anal Bioanal Chem 407:6873\u20136878. \n                    https:\/\/doi.org\/10.1007\/s00216-015-8846-4","journal-title":"Anal Bioanal Chem"},{"key":"2571_CR24","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.jmoldx.2016.09.009","volume":"19","author":"L Sorber","year":"2017","unstructured":"Sorber L, Zwaenepoel K, Deschoolmeester V, Roeyen G, Lardon F, Rolfo C, Pauwels P (2017) A comparison of cell-free DNA isolation kits. J Mol Diagnostics 19:162\u2013168. \n                    https:\/\/doi.org\/10.1016\/j.jmoldx.2016.09.009","journal-title":"J Mol Diagnostics"},{"key":"2571_CR25","doi-asserted-by":"publisher","unstructured":"Markus H, Contente-Cuomo T, Farooq M, Liang WS, Borad MJ, Sivakumar S, Gollins S, Tran NL, Dhruv HD, Berens ME, Bryce A, Sekulic A, Ribas A, Trent JM, LoRusso PM, Murtaza M (2018) Evaluation of pre-analytical factors affecting plasma DNA analysis. Sci Rep 8(7375). \n                    https:\/\/doi.org\/10.1038\/s41598-018-25810-0","DOI":"10.1038\/s41598-018-25810-0"},{"key":"2571_CR26","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1016\/j.clinbiochem.2013.06.002","volume":"46","author":"SE Norton","year":"2013","unstructured":"Norton SE, Lechner JM, Williams T, Fernando MR (2013) A stabilizing reagent prevents cell-free DNA contamination by cellular DNA in plasma during blood sample storage and shipping as determined by digital PCR. Clin Biochem 46:1561\u20131565. \n                    https:\/\/doi.org\/10.1016\/j.clinbiochem.2013.06.002","journal-title":"Clin Biochem"},{"key":"2571_CR27","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1038\/nrclinonc.2013.110","volume":"10","author":"E Crowley","year":"2013","unstructured":"Crowley E, Di Nicolantonio F, Loupakis F, Bardelli A (2013) Liquid biopsy: monitoring cancer-genetics in the blood. Nat Rev Clin Oncol 10:472\u2013484. \n                    https:\/\/doi.org\/10.1038\/nrclinonc.2013.110","journal-title":"Nat Rev Clin Oncol"},{"key":"2571_CR28","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1634\/theoncologist.2016-0082","volume":"21","author":"B Levy","year":"2016","unstructured":"Levy B, Hu ZI, Cordova KN, Close S, Lee K, Becker D (2016) Clinical utility of liquid diagnostic platforms in non-small cell lung Cancer. Oncologist 21:1121\u20131130. \n                    https:\/\/doi.org\/10.1634\/theoncologist.2016-0082","journal-title":"Oncologist"},{"key":"2571_CR29","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1016\/j.jtho.2018.05.030","volume":"13","author":"C Rolfo","year":"2018","unstructured":"Rolfo C, Mack PC, Scagliotti GV, Baas P, Barlesi F, Bivona TG, Herbst RS, Mok TS, Peled N, Pirker R, Raez LE, Reck M, Riess JW, Sequist LV, Shepherd FA, Sholl LM, Tan DSW, Wakelee HA, Wistuba II, Wynes MW, Carbone DP, Hirsch FR, Gandara DR (2018) Liquid biopsy for advanced non-small cell lung Cancer (NSCLC): a statement paper from the IASLC. J Thorac Oncol 13:1248\u20131268. \n                    https:\/\/doi.org\/10.1016\/j.jtho.2018.05.030","journal-title":"J Thorac Oncol"},{"key":"2571_CR30","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1038\/nrc3066","volume":"11","author":"H Schwarzenbach","year":"2011","unstructured":"Schwarzenbach H, Hoon DSB, Pantel K (2011) Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer 11:426\u2013437. \n                    https:\/\/doi.org\/10.1038\/nrc3066","journal-title":"Nat Rev Cancer"},{"key":"2571_CR31","doi-asserted-by":"publisher","unstructured":"Luo J, Shen L, Zheng D (2014) Diagnostic value of circulating free DNA for the detection of EGFR mutation status in NSCLC: a systematic review and meta-analysis. Sci Rep 4(6269). \n                    https:\/\/doi.org\/10.1038\/srep06269","DOI":"10.1038\/srep06269"},{"key":"2571_CR32","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0140712","volume":"10","author":"RB Lanman","year":"2015","unstructured":"Lanman RB, Mortimer SA, Zill OA, Sebisanovic D, Lopez R, Blau S, Collisson EA, Divers SG, Hoon DSB, Kopetz ES, Lee J, Nikolinakos PG, Baca AM, Kermani BG, Eltoukhy H, Talasaz AA (2015) Analytical and clinical validation of a digital sequencing panel for quantitative, highly accurate evaluation of cell-free circulating tumor DNA. PLoS One 10:e0140712. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0140712","journal-title":"PLoS One"},{"key":"2571_CR33","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1158\/1078-0432.CCR-15-1627-T","volume":"22","author":"CP Paweletz","year":"2016","unstructured":"Paweletz CP, Sacher AG, Raymond CK, Alden RS, O'Connell A, Mach SL, Kuang Y, Gandhi L, Kirschmeier P, English JM, Lim LP, Ja nne PA, Oxnard GR (2016) Bias-corrected targeted next-generation sequencing for rapid, multiplexed detection of actionable alterations in cell-free DNA from advanced lung Cancer patients. Clin Cancer Res 22:915\u2013922. \n                    https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-1627-T","journal-title":"Clin Cancer Res"},{"key":"2571_CR34","doi-asserted-by":"publisher","unstructured":"Chabon JJ, Simmons AD, Lovejoy AF, Esfahani MS, Newman AM, Haringsma HJ, Kurtz DM, Stehr H, Scherer F, Karlovich CA, Harding TC, Durkin KA, Otterson GA, Purcell WT, Camidge DR, Goldman JW, Sequist LV, Piotrowska Z, Wakelee HA, Neal JW, Alizadeh AA, Diehn M (2016) Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients. Nat Commun 7(11815). \n                    https:\/\/doi.org\/10.1038\/ncomms11815","DOI":"10.1038\/ncomms11815"},{"key":"2571_CR35","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1158\/1078-0432.CCR-17-1341","volume":"24","author":"SB Goldberg","year":"2018","unstructured":"Goldberg SB, Narayan A, Kole AJ, Decker RH, Teysir J, Carriero NJ, Lee A, Nemati R, Nath SK, Mane SM, Deng Y, Sukumar N, Zelterman D, Boffa DJ, Politi K, Gettinger SN, Wilson LD, Herbst RS, Patel AA (2018) Early assessment of lung Cancer immunotherapy response via circulating tumor DNA. Clin Cancer Res 24:1872\u20131880. \n                    https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-1341","journal-title":"Clin Cancer Res"},{"key":"2571_CR36","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1136\/jclinpath-2014-202404","volume":"67","author":"IA Cree","year":"2014","unstructured":"Cree IA, Deans Z, Ligtenberg MJL, Normanno N, Edsj\u00f6 A, Rouleau E, Sol\u00e9 F, Thunnissen E, Timens W, Schuuring E, Dequeker E, Murray S, Dietel M, Groenen P, van Krieken JH (2014) Guidance for laboratories performing molecular pathology for cancer patients. J Clin Pathol 67:923\u2013931. \n                    https:\/\/doi.org\/10.1136\/jclinpath-2014-202404","journal-title":"J Clin Pathol"},{"key":"2571_CR37","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s00428-016-2025-7","volume":"470","author":"ZC Deans","year":"2017","unstructured":"Deans ZC, Costa JL, Cree I et al (2017) Integration of next-generation sequencing in clinical diagnostic molecular pathology laboratories for analysis of solid tumours; an expert opinion on behalf of IQN path ASBL. Virchows Arch 470:5\u201320. \n                    https:\/\/doi.org\/10.1007\/s00428-016-2025-7","journal-title":"Virchows Arch"},{"key":"2571_CR38","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1002\/humu.22981","volume":"37","author":"JT Dunnen den","year":"2016","unstructured":"den Dunnen JT, Dalgleish R, Maglott DR, Hart RK, Greenblatt MS, McGowan-Jordan J, Roux AF, Smith T, Antonarakis SE, Taschner PEM, on behalf of the Human Genome Variation Society (HGVS), the Human Variome Project (HVP), and the Human Genome Organisation (HUGO) (2016) HGVS recommendations for the description of sequence variants: 2016 update. Hum Mutat 37:564\u2013569. \n                    https:\/\/doi.org\/10.1002\/humu.22981","journal-title":"Hum Mutat"},{"key":"2571_CR39","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0058177","volume":"8","author":"AS Whale","year":"2013","unstructured":"Whale AS, Cowen S, Foy CA, Huggett JF (2013) Methods for applying accurate digital PCR analysis on low copy DNA samples. PLoS One 8:e58177. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0058177","journal-title":"PLoS One"}],"container-title":["Virchows Archiv"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-019-02571-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00428-019-02571-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-019-02571-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,24]],"date-time":"2020-04-24T23:11:09Z","timestamp":1587769869000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00428-019-02571-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,26]]},"references-count":39,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["2571"],"URL":"https:\/\/doi.org\/10.1007\/s00428-019-02571-3","relation":{},"ISSN":["0945-6317","1432-2307"],"issn-type":[{"value":"0945-6317","type":"print"},{"value":"1432-2307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,26]]},"assertion":[{"value":"21 June 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare the following conflict of interest:Schuuring E performed lectures for Illumina, Novartis, Pfizer, BioCartis; is consultant in advisory boards for AstraZeneca, Pfizer, Novartis, BioCartis; and received financial support from Roche, Biocartis, BMS, Pfizer (all fees to the Institution).Deans ZC is consultant in advisory boards for AstraZeneca and Roche.Butler R is a consultant in advisory boards for AstraZeneca, Novartis, Roche, Pfizer, Bristol-Myers Squibb.All authors contributed equally to the design and delivery of the workshop, and preparation of the manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The authors comply with the Ethical Standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}